LEADER 04687nam 2201153z- 450 001 9910557495503321 005 20231214133607.0 035 $a(CKB)5400000000042876 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69256 035 $a(EXLCZ)995400000000042876 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aArteriogenesis and Therapeutic Neovascularization 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (220 p.) 311 $a3-03936-593-2 311 $a3-03936-594-0 330 $aFor many years, arteriogenesis, also called collateral formation, has been regarded as being a beneficial process to restore blood flow to distal tissues in occluded arteries. Therefore, it is frequently referred to in relation to therapeutic angiogenesis. Despite the big clinical potential and the many promising clinical trials on arteriogenesis and therapeutic angiogenesis, the exact molecular mechanisms involved in the multifactorial processes of arteriogenesis are still not completely understood. A better understanding is needed in order to define successful clinical therapies. In this Special Issue, multiple aspects of arteriogenesis and therapeutic angiogenesis will be addressed, ranging from the role of inflammatory processes and immune cells, to growth factors, microRNAs and environmental factors like hypoxia. Therapeutic angiogenesis will also be discussed in relation to the atherosclerosis and intraplaque angiogenesis in hypoxic lesions, as well as specific forms of arteriogenesis in relation to spinal cord blood supply and aorta surgery. The effects of exercise, a frequently prescribed therapy for PAD patients, on arteriogenesis are also discussed. Overall, the papers in this Special Issue on arteriogenesis and therapeutic angiogenesis provide important new insights in the underlying pathophysiological mechanism of these complex processes and may be helpful to define a successful future intervention directed at therapeutic angiogenesis. 606 $aMedicine$2bicssc 610 $afactor VII activating protease 610 $aHABP2 610 $aVEGF 610 $amatrigel 610 $aneo-vascularization 610 $ahind limb ischemia 610 $aangiogenesis 610 $aarteriogenesis 610 $aERK 610 $aendothelial cells 610 $ainflammation 610 $amacrophages 610 $aatherosclerosis 610 $apericyte 610 $arAAV 610 $acapillary 610 $amicroRNA 610 $aisomiRs 610 $aepitranscriptome 610 $aneovascularization 610 $aA-to-I editing 610 $am6A 610 $aRNA modifications 610 $aRNA methylation 610 $alower extremity arterial disease 610 $aperipheral arterial disease 610 $ablood flow restriction 610 $aactivity-based benefits 610 $atraining effects 610 $aeffect mechanism 610 $ahyperoxygenation 610 $avein graft disease 610 $avascular biology 610 $aspinal cord ischemia 610 $aparaplegia 610 $aaortic disease 610 $aTAAA 610 $acollateral network 610 $aparaspinous compartment 610 $aNO 610 $aNOTCH 610 $ainnate immunity 610 $amast cell 610 $aGH and eNOS 610 $aIGF-I 610 $aoxidative stress and arterial inflammation 610 $avascular homeostasis 610 $aGHAS trial 610 $acollateral artery growth 610 $aSMC proliferation 610 $apotassium channel 610 $aKV1.3 610 $aKCa3.1 610 $aFGFR-1 610 $aEgr-1 610 $aPDFG-R 610 $a?SM-actin 610 $aTLR2/6 610 $afemoral artery ligation 610 $ablood flow recovery 610 $acollateral growth 610 $aVHL loss of function 610 $amicroRNA-212/132 615 7$aMedicine 700 $aDeindl$b Elisabeth$4edt$01294156 702 $aQuax$b Paul$4edt 702 $aWaltenberger$b Johannes$4edt 702 $aSchmitz-Rixen$b Thomas$4edt 702 $aDeindl$b Elisabeth$4oth 702 $aQuax$b Paul$4oth 702 $aWaltenberger$b Johannes$4oth 702 $aSchmitz-Rixen$b Thomas$4oth 906 $aBOOK 912 $a9910557495503321 996 $aArteriogenesis and Therapeutic Neovascularization$93022943 997 $aUNINA